Who are Nesacaine-Mpf's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): xylocain, Ropivacain, Chlorprocaine, Lidocain, Lignocaine, Naropeine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/chloroprocaine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Nesacaine-Mpf — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nesacaine-Mpf (CHLOROPROCAINE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Ester Local Anesthetic. Area: Pain.

marketed Ester Local Anesthetic Sodium channel protein type 10 subunit alpha Pain Small molecule Live · refreshed every 30 min

Target snapshot

Nesacaine-Mpf (CHLOROPROCAINE) — Fresenius Kabi.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Nesacaine-Mpf TARGET	CHLOROPROCAINE	Fresenius Kabi	marketed	Ester Local Anesthetic	Sodium channel protein type 10 subunit alpha	1955-01-01
xylocain	xylocain	Saint-Joseph University	marketed		5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha
Ropivacain	Ropivacain	University Hospital, Basel, Switzerland	marketed		Potassium channel subfamily K member 3, Sodium channel protein type 1 subunit alpha, Sodium channel protein type 10 subunit alpha
Chlorprocaine	Chlorprocaine	Hadassah Medical Organization	marketed		Sodium channel protein type 10 subunit alpha
Lidocain	Lidocain	Bayer	marketed		5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha
Lignocaine	Lignocaine	University of Malaya	marketed		5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha
Naropeine	Naropeine	University Hospital, Rouen	phase 3		Potassium channel subfamily K member 3, Sodium channel protein type 1 subunit alpha, Sodium channel protein type 10 subunit alpha

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Ester Local Anesthetic class)

Alcon Labs · 1 drug in this class
Fresenius Kabi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Nesacaine-Mpf — Competitive Intelligence Brief. https://druglandscape.com/ci/chloroprocaine. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing